Jul-04 -

Soft Tissue & Bone

EORTC 62005 – Phase III randomized, intergroup, international trial assessing the clinical activity of STI-571 at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumours (GIST) expressing the KIT receptor tyrosine kinase (CD117).

In 2004, EORTC published results of an additional clinical trial, where it optimized the dosage for the timatinub treatment of advanced or metastatic gastrointestinal stromal tumour (GIST).

READ MORE

Go to Top